Drug intelligence / Profile preview

PFKR

Development stage: Preclinical
Lead developer: Asahi Kasei
Modality: IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

PFKR is a humanized monoclonal antibody being developed by Chiome Bioscience for the treatment of secondary progressive multiple sclerosis (SPMS). It targets CX3CR1 (also known as the fractalkine receptor), a G protein-coupled receptor that mediates the migration of immune cells to sites of inflammation. By inhibiting CX3CR1, PFKR aims to reduce neuroinflammation associated with SPMS. In November 2024, Chiome Bioscience entered into an exclusive license agreement with Asahi Kasei Pharma for the development and commercialization of the drug. It is currently in the preclinical stage of development.

Other names: anti-CX3CR1 antibodyanti-CX-3CR1 antibodyanti-CX 3CR1 antibody

Targets

CX3CR1 (C-X3-C motif chemokine receptor 1)

Beyond the preview

Go deeper on PFKR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PFKR.

Explore the full profile